Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGN-CD33A + Standard of Care in Newly Diagnosed AML
NCT02326584Phase 1Completed
- Sponsor
- Seagen Inc.
- Start
- Dec 2014
- Primary completion
- Jan 2017
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of vadastuximab talirine in acute myeloid leukemia (AML) (4 arms), sponsored by Seagen Inc. Primary endpoints: Incidence of adverse events, Incidence of laboratory abnormalities and 1 more. Started Dec 2014; status: completed.
02
Drugs
vadastuximab talirine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02326584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02326584.